Genmab — Februar 2021

Helge_LarsenPI-redaktør

Asien: Fremgang overalt - Hongkong undtagethttps://www.proinvestor.com/investornyt/671711/asien-fremgang-overalt-hongkong-undtaget

Helge_LarsenPI-redaktør

Onsdagens aviser med Coloplast, Novozymes og Bavarian https://www.proinvestor.com/investornyt/671710/onsdagens-aviser-med-coloplast-novozymes-og-bavarian

E_L

Amgen's BCMA Bispecific: AMG 701 Enrollment in the Phase 1 study has been paused while we discuss protocol modifications to optimize safety monitoring and mitigation with the FDA. Currently enrolled patients who are demonstrating benefit may continue to receive investigational product and the Company expects to resume patient enrollment in H1 2021. (Teclistamab rival)

E_L

they are also pausing a CD33 bispecific

E_L

"Uptake of KYPROLIS in combination with DARZALEX (daratumumab) plus dexamethasone (DKd) in the U.S. has been encouraging as reflected in new patient share, and we expect this momentum to continue into 2021 with additional global regulatory approvals of the DKd combination."

Klarussen

Det er godt nok ikke mange Genmab`ber der omsættes de her dage...

AaBforever

"Der er så stille nu"...måske stilhed før storm:-)

Solsen

Der er vel ikke forventelige nyheder lige om hjørnet. Så en rolig periode lidt endnu før vi skal se regnskabet og guidance

E_L

AbbVie Humira sales $19,8bn..... Good practice run for Epco

Gourvin

Besynderligt dagligt mønster fra Genmab. Starter som lyn og torden. Falder omkring middag, som de fleste danske aktier for så at fortsætte i hullet ved lukkeauktionen!

AaBforever

ADS US under 40

E_L

Genmab
@Genmab
A recent article published in
@berlingske
a leading newspaper in Denmark featured Jan van de Winkel, our President and CEO. https://twitter.com/Genmab/status/1357023579267825665